n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, August 16th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Oxis International, Inc. (OXIS)

Money Morning, TopPennyStockMovers, Marketbeat.com, Cannabis Financial Network News, Gryphon Digest, PennyStocks24, Equity Observer, Value Penny Stocks, Real Pennies, HoleinOneStocks.net, Pumps and Dumps, 007 Stock Chat, Ascending Stocks, BestStocksDaily, Capital Equity Report, HotStockProfits, and Penny Stock Rumble reported earlier on Oxis International, Inc. (OXIS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Oxis International, Inc. is a developer of unique drugs centered on the treatment of cancer and other unmet medical needs. The Company’s drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC).  In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. Oxis is targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma, and more with highly potent biopharmaceutical drugs designed for targeted therapy. Oxis Biotech, Inc. is a wholly-owned subsidiary of Oxis International (Tampa, Florida).

The Company’s lead drug candidate, OXS-1550 (DT2219ARL), is a novel bispecific scFv recombinant fusion protein-drug conjugate. It consists of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors.

When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed because of the action of the drug's cytotoxic payload.  OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. Oxis Biotech earlier executed an exclusive world-wide license agreement to further develop and commercialize OXS-1550.   

The Company’s OXS-4235 is a small molecule therapeutic candidate. It targets the treatment of multiple myeloma and associated osteolytic lesions.  In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and lessen osteolytic lesions in bone. Also, Oxis Biotech is continuing to concentrate on a cure for the Zika virus.

A patent was issued on February 28, 2017 from the U.S. Patent and Trademark Office (USPTO) for Oxis International’s drug candidate OXIS-4235 for the treatment of multiple myeloma. The patent clears the way for the Company’s subsidiary, Oxis Biotech, to start the process of pursuing clinical trials for the new drug.

The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma. Dr. Sean Xie of Pittsburgh, Pennsylvania developed the drug. Oxis Biotech, by way of its licensing agreement with Dr. Xie, holds the exclusive international rights to commercialize this technology.

Recently, Oxis International and Euronext Paris, parent of Oxis Biotech, announced that the USPTO approved and issued Patent No. 9,580,382 for its drug candidate OXIS-4235 for the treatment of myeloma. This patent clears the way for Oxis Biotech to start the process of pursuing clinical trials for OXIS-4235.

On July 25, 2017, Oxis International and Euronext Paris disclosed in an 8-K filing that it published a slide deck on its website (www.oxis.com). The slide deck provides more detail regarding its agreement to acquire Georgetown Translational Pharmaceuticals, Inc. (GTP) and how the deal will add value to Oxis. Additionally, Oxis International initiated a name change to GT Biopharma, Inc. as part of its acquisition and 14C filing.

Earlier this month, Oxis International (GT Biopharma) and Euronext Paris announced that four patients have been enrolled in the Company's Food and Drug Administration-approved (FDA) Phase 2 clinical trial of its promising cancer therapy, OXS-1550.

Oxis International, Inc. (OXIS), closed Wednesday's trading session at $0.094, down 4.57%, on 20,593,179 volume with 1,716 trades. The average volume for the last 60 days is 4,436,559 and the stock's 52-week low/high is $0.01/$0.298.

Digatrade Financial Corp. (DIGAF)

MarketWatch, Bloomberg, InvestorsHub, and The Wall Street Journal reported on Digatrade Financial Corp. (DIGAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Digatrade Financial Corp. is a global digital asset exchange and blockchain development services company. It engages in the licensing, development, and branding of a digital exchange trading platform and a peer to peer electronic payment processing network for enabling users to trade fiat and alternative currencies. Basically, DIGATRADE is a Digital Asset, Currency (Bitcoin) Exchange, and Internet Financial Services Company owned and operated by Digatrade Financial Corp.

Digatrade Financial is based in Vancouver, British Columbia. Formed in 2000, the Company lists on the OTC Markets Group’s OTCQB. It previously went by the name Bit-X Financial Corporation. It changed its name to Digatrade Financial Corp. in October of 2015.

Digatrade Financial provides operational support specializing in web-based digital currency exchange and transaction services for the cryptographic digital currencies. This includes Bitcoin and other alternative digital coins. The Company provides a user-friendly, secure, and affordable platform to purchase and sell Bitcoin and other digital assets. Digatrade provides a 24-hour online platform. This platform provides the automated matching of orders between its registered members.

The proprietary Digatrade trading and matching engine manages high volume, high throughput, and low latency trading. Furthermore, this engine features blended multi-currency settlement in addition to real time FX pricing and risk management fully powered by ANX Technologies. The order engine delivers pre-scan indicative pricing. Users can choose to either fix the quantity of Bitcoins or fix the price paid for every order.

Digatrade Financial announced in April 2017, the execution of a definitive agreement with No Limits Consulting Ltd. (d/b/a: ANX International, ANX Technologies & ANXPRO) based in Hong Kong. Under new financial terms, Digatrade has re-positioned itself to continue its development with its core digital asset exchange platform. This is while centering on the implementation of new Initial Digital Offerings (IDO's) for institutional customers, marketing, and brand awareness.

Digatrade has launched the Digatrade OTC Trade Desk. The new Digatrade Over-the-Counter (OTC) trading service will let KYC verified customers to complete trades outside the online liquidity order book at competitive market prices.

At present, Digatrade Financial is developing a number of new technologies for the Digatrade Core 2.0 Digital Asset Trading Platform. In addition, the Company is seeking more new opportunities and partners for growth as Bitcoin (BTC) continues to grow in value with a market capitalization now surpassing $23.5 Billion.

Digatrade Financial Corp. (DIGAF), closed Wednesday's trading session at $0.282, up 88.00%, on 6,475,768 volume with 997 trades. The average volume for the last 60 days is 333,596 and the stock's 52-week low/high is $0.021/$1.04.

Research Solutions, Inc. (RSSS)

Marketbeat and Wall Street Resources reported earlier on Research Solutions, Inc. (RSSS), and we also report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Research Solutions, Inc. is an innovator in providing cloud-based solutions for scientific research. The Company is a pioneer in cloud-based SaaS (Software-as-a-Service) research intelligence products and services for research-intensive organizations. Research Solutions has its wholly-owned subsidiary Reprints Desk, Inc. The Company’s cloud-based SaaS platform provides customers with on demand access to, and augmented data from, tens of millions of scientific, medical, and technical (STM) documents. This is in addition to tens of millions of articles beforehand published.  Research Solutions has its corporate headquarters in Encino, California.

Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions, medical affairs, and scientific, technical, and medical (STM) research. Reprints Desk and Altmetric LLP previously agreed to integrate Altmetric badges to scholarly content obtained via Reprints Desk's award-winning research retrieval platform Article Galaxy. Altmetric is a top research metrics provider.

The Altmetric badges provide an at-a-glance visualization of the attention a particular journal article has received online from mainstream and social media, public policy documents, blogs, Wikipedia, and scholarly forums. These help scientists in assessing the reach and influence of research.

Research Solutions and its wholly-owned subsidiary Reprints Desk have launched a new version of the Company's award-winning Article Galaxy research platform. New features include full mobile responsiveness, design enhancements, an improved order history page, and the introduction of an ecosystem of gadgets - robust applications that allow for sophisticated data augmentation of content.

Reprints Desk has signed separate reseller agreements with Ritme and Alfasoft to deliver new tools and services that address the complete range of knowledge acquisition and information management requirements of researchers in scientific, technical, and also medical (STM) fields.

In May, Research Solutions reported financial results for its fiscal Q3 ended March 31, 2017. Total revenue was $8.6 million versus $8.7 million in the year-ago quarter. Platform revenue was up 124 percent to $270,920, with a 152 percent increase in total Platform deployments to 116. Annual recurring revenue was up 127 percent to $1.1 million.

Customer count was up 9 percent to 985. Transaction count was up 7 percent to 212,827. Transaction revenue was basically unchanged at $6.4 million.  Net loss was $(0.6) million, or $(0.03) per share, versus net income of $32,000 or $0.00 per share. This loss was because of Research Solutions’ continued investment in its rapidly growing, recurring revenue Platform business.

Recently, Outsell, Inc. gave Research Solutions and Reprints Desk top ratings for its recently released version of the Article Galaxy SaaS research platform. Outsell is the globe’s only research and advisory firm centered on media, information, and technology. The Outsell Insights published on April 21, 2017 concludes that Reprints Desk is delivering a considerably improved service to researchers, which provides an enhanced user experience and creates efficiencies within end-user workflows focused around app-like gadgets.

Research Solutions, Inc. (RSSS), closed Wednesday's trading session at $1.00, even for the day. The average volume for the last 60 days is 6,530 and the stock's 52-week low/high is $0.66/$1.2207.

AmeriCann, Inc. (ACAN)

Promotion Stock Secrets, TopPennyStockMovers, Cannabis Financial Network News, OTC Markets Group, SmallCapVoice, Real Pennies, and TheMicrocapNews reported earlier on AmeriCann, Inc. (ACAN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

An Agricultural Technology company, AmeriCann, Inc. is developing sustainable, state-of-the-art medical cannabis cultivation properties. The Company is a national leader of sustainable cultivation and processing infrastructure for the medical marijuana industry. It designs, builds, as well as owns efficient cultivation and processing facilities to produce medical cannabis. It is developing projects across the nation in regulated markets by way of the “Preferred Partner Program”.  OTCQB-listed, AmeriCann has its headquarters in Denver, Colorado.

The Company has a multi-market growth strategy with an existing portfolio of more than 1,000,000 sq. ft. of sustainable cannabis production infrastructure in development. AmeriCann’s mission is to serve medical cannabis patients through providing facilities designed and constructed to produce high quality, consistent medicine, cultivated and processed in a controlled, secure, and sustainable environment.

The Company identifies, acquires, and develops real estate particularly suited for cannabis operations. AmeriCann finances real estate development. Additionally, it provides necessary venture capital to developing cannabis enterprises.

In May, AmeriCann announced the hiring of Dr. Brian Corr as Director of Horticultural Science and Operations. He is a 40-year veteran in the traditional horticulture industry with companies such as Ball Horticulture and Syngenta (SYT). Dr. Corr is a renowned expert in controlled-environment horticulture. He will lead AmeriCann's management services division.

In June, AmeriCann announced that it completed a very successful three-year partnership with a licensed Colorado cannabis producer, which resulted in excellent returns to the Company. AmeriCann contributed $1,000,000 in secured funding in 2014 for the final design and construction of a 15,000-square foot state-of-art cultivation and processing facility in Denver, Colorado. Its Preferred Partner, 4900 Jackson, LLC, has been a licensed medical cannabis producer in Colorado since 2010.

With the final payment made in May of 2017, AmeriCann received total distributions over the term of the agreement of $1,457,000. This was from consulting fees, interest, and principal repayment. The average yearly returns surpassed 15 percent over the 3 years.

At the end of July, AmeriCann announced strong support for the milestone adult use cannabis bill signed by Massachusetts Governor Charlie Baker on July 28, 2017. The new law implements the successful ballot measure approved by voters in November 2016. Massachusetts is the first state in the eastern United States to legalize the adult use of marijuana.

AmeriCann, Inc. (ACAN), closed Wednesday's trading session at $1.75, down 1.12%, on 45,651 volume with 67 trades. The average volume for the last 60 days is 50,945 and the stock's 52-week low/high is $0.30/$2.75.

BTCS, Inc. (BTCS)

RedChip, PennyPro, Stock Commander, HotStockProfits, Value Penny Stocks, Money Morning, 1-2-3 Stock Alerts, Fortune Stock Alerts, Penny Stock Circle, StockMarketQuote.us, StockMister, SmallCapVoice, AddictivePennyStocks, Bullseyestox, PennyStockRumors.net, PennyStocks Forever, PricelessPenny, and TheMicrocapNews reported on BTCS, Inc. (BTCS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BTCS, Inc. is a blockchain technology focused company headquartered in Silver Spring, Maryland. The Company is an early entrant in the Digital Asset market. In addition, it is one of the first U.S. publicly traded companies engaged with Digital Assets and blockchain technologies. Blockchains are distributed public ledgers, which can fundamentally influence all industries around the world that require trust and rely on or use record keeping.  The Company has a record of accomplishment of accurate digital asset trend prediction. BTCS’ shares trade on the OTC Markets Group’s OTCQB.

BTCS’ plan (subject to additional financing) is to create a portfolio of digital assets, such as bitcoin and other "protocol tokens", to provide investors a diversified pure-play exposure to the bitcoin and blockchain industries. The Company’s intention is to acquire digital assets by way of open market purchases; and participating in initial digital asset offerings (or initial coin offerings).

Furthermore, BTCS may acquire digital assets through resuming its transaction verification services business (or mining) via outsourced data centers and earning rewards in digital assets by securing their respective blockchains. Moreover, the Company is concentrating on growth via acquisition.

A blockchain is secured and maintained by a network of specialized servers (nodes) globally. All transactions are publicly available on a blockchain. Transactions undergo verification and confirmation through nodes worldwide before being added to a blockchain.

Last month, BTCS announced the appointment of Mr. Jonathon R. Read to its Board of Directors. Mr. Read has held many executive positions with domestic and global companies over a career, which spans more than 35 years. Most recently, from 2013 to the present, he has served as Managing Partner of Quadratam1 LLC (Scottsdale, Arizona) a firm specializing in providing financial and organizational consulting services for growth-stage companies in the United States and China.

Before that, Mr. Read served as Chief Executive Officer (CEO) or President of Timefire VR, Inc., previously known as EnergyTek Corp. During his tenure, he repositioned, re-financed, and merged the company into an entity centered on the virtual reality sector. 

Mr. Charles Allen, BTCS CEO, said, "Jonathon brings a wealth of public company expertise to our board. As we move forward on our plans to build a vertically-integrated operation in the burgeoning blockchain space, Jonathon's experience should add tremendous value."

BTCS, Inc. (BTCS), closed Wednesday's trading session at $0.255, down 10.56%, on 25,191,267 volume with 3,630 trades. The average volume for the last 60 days is 5,568,811 and the stock's 52-week low/high is $0.0285/$0.578.

graphic

The QualityStocks
Company Corner

graphic
graphic

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.08, up 14.29%, on 10,100 volume with 2 trades. The stock’s average daily volume over the past 60 days is 9,350 and its 52-week low/high is $0.0001/$0.62.

Algae Dynamics Corp. (ADYNF) today announced that it has further refined its relationship with 6779264 Manitoba Ltd dba Bonify ("Bonify") in a Letter of Intent ("LOI") dated August 10, 2017. Bonify is a Licensed Producer, pursuant to the Access to Cannabis for Medical Purposes Regulations in Canada, with the capability to grow multiple strains of cannabis in its state-of-the-art 320,000 square foot facility.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Enters Into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products; Accelerates Go-to-Market Strategy

NetworkNewsWire Releases Exclusive Audio Interview with Algae Dynamics Corp. (ADYNF)

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.715, up 4.46%, on 179,393 volume with 119 trades. The stock’s average daily volume over the past 60 days is 45,404 and its 52-week low/high is $0.6171/$0.90.

NetworkNewsWire ("NNW"), today announced the publication of an editorial featuring ABcann Global (TSX VENTURE: ABCN) (OTCQB: ABCCF), a client of NNW that is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. The publication, titled, "Green Rush taking Hold in Canada as US Lawmakers Continue to Spin Tires," discusses several public companies rushing to make their mark on the expanding Canadian cannabis market. To view the full publication, visit: https://www.networknewswire.com/green-rush-taking-hold-canada-us-lawmakers-continue-spin-tires/

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

NetworkNewsWire Announces Publication Discussing the Companies Ready to Strike on the Canadian Legal Marijuana Industry

ABcann Goes from RTO to $43 Million in Cash in 3 Months -- CFN Media

ABcann and Cannabis Wheaton Announce Closing of $15 Million Investment

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.405, up 7.91%, on 86,594 volume with 39 trades. The stock’s average daily volume over the past 60 days is 57,413 and its 52-week low/high is $0.05/$2.09.

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announced today that it has received US$91,443.50 from the exercise of warrants and options previously granted. The stock warrants were exercised at the price of US$0.14 and the stock options were exercised at US$0.2273 for a total of 636,025 common shares being issued. All warrants and options are being exercised by third parties who are neither officers nor directors of the Company.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Announces Exercised Warrants and Options

CEO Chris Bunka was Interviewed on Uptick Network Discussing Company’s Positive Future Progress

Lexaria Bioscience Corp. Engages NetworkNewsWire for Corporate Communications Solutions

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.78, up 1.30%, on 101,716 volume with 35 trades. The stock’s average daily volume over the past 60 days is 54,449 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (OTC: ORHB), today announced the launch of its new orthopedic service lines for total joint replacement, as well as the adoption of the modules by the Company's existing customers. Notably, among this customer base is a major hospital which now utilizes the ORHub Surgical Management Platform for all surgeries performed at its facility.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Announces Major Expansion of Operations with Launch and Adoption of Orthopedic Service Lines

ORHub, Inc. Signs National Sales Partner to Launch Transformative Medical Software in Major U.S. Markets

ORHub, Inc. Introduces Fourth Medical Software Service Line, Continuing Rapid Expansion Strategy

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0693, off by 17.40%, on 46,580,391 volume with 2,326 trades. The stock’s average daily volume over the past 60 days is 17,589,713, and its 52-week low/high is $0.0075/$0.415.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of NNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication, titled, "Record Bitcoin Gains Indicate High Times Ahead for Cannabis Cryptocurrency," discusses the flourishing potential of cryptocurrency as a prime solution in the unbankable cannabis sector. To view the full publication, visit: https://www.networknewswire.com/record-bitcoin-gains-indicate-high-times-ahead-cannabis-cryptocurrency/

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Highlighting Investment Prospects Employing Cryptocurrency in the Legal Marijuana Industry

SinglePoint Invests in WeedCoin Cryptocurrency -- CFN Media

NetworkNewsWire Announces Publication Discussing Bitcoin's Potential to Fill the Void of Federal Banking Resources in the Legal Marijuana Industry

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Trader Power News
(DGLT) +435.24%

2.

Penny Stock Mobsters
(TMXN) +91.89%

3.

PoliticsAndMyPortfolio
(DIGAF) +88.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251